Key facts
- Arbor Biotechnologies’s last known valuation is $238.9M (Oct 2025).
- It has raised $304.5M across 2 recorded rounds; the latest was Later Stage VC ($215.0M) in Oct 2021.
- Notable investors include Temasek Holdings, Samsung Venture Investment, Alexandria Venture Investments, ARCH Venture Partners, Qatar Investment Authority — 31 tracked in total.
- Arbor Biotechnologies has filed 3 Form Ds with the SEC since 2017, most recently Nov 2021 ($215.0M sold to 37 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 31 names
- ·Watchlist + deal alerts for Arbor Biotechnologies
Funding rounds
2 roundsAbout Arbor Biotechnologies
Developer of genomic tools designed to improve human health and sustainability. The company's tools use AI and machine learning to aggregate genomic sequence data to improve and streamline future cycles of curative treatments for previously incurable genetic diseases, enabling drug developers to replace whole genes and to precisely correct mutations to treat all patients with genetic diseases.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2016
- Employees
- 110
- Website
- arbor.bio/
- Ownership
- Privately Held (backing)
Arbor Biotechnologies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Arbor Biotechnologies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Arbor Biotechnologies in its N-PORT filings yet. We sweep new filings monthly.